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Introduction
The cell division control 37 (CDC37) protein plays a fundamental role in chaperoning the protein kinase family and participates in cancer by maintaining the activity of protein kinases involved in cell proliferation and transformation. These include tyrosine kinases such as Src [1] , and serine/threonine kinases in the Raf-ERK pathway [2] , Akt [3] , the inhibitor of NF-κB kinase (IKK) [4] , and cyclin-dependent kinase 4 (CDK4) [5] [6] [7] . CDC37 functions primarily in a complex with heat shock protein 90 (HSP90) to mediate the 3-dimensional folding and structural integrity of client proteins kinases [1, 8, 9] . CDC37 is particularly significant in prostate cancer as its overexpression leads to prostate carcinogenesis in transgenic mice [10] [11] [12] . It has been suggested that the high levels of oncogenic proteins present in most cancers make them dependent on molecular chaperones, a state referred to as "chaperone addiction" [13, 14] . Thus, because of their large protein clienteles, the CDC37-HSP90 axis offers a critical target for inactivating multiple oncogenic pathways [13, 14] . Consequently, the inhibition of HSP90 in cancer is currently a major area of research [14, 15] . However, less is known regarding the regulation of CDC37 expression in cancer and we have addressed this deficiency in this study.
Examination of the CDC37 5' upstream region and introns indicated multiple consensus sequences that are potentially bound by the transcription factor Myeloid Zinc Finger 1 (MZF1, a.k.a. ZSCAN6, ZNF42, ZFP98). We recently reported that frequent amplification of MZF1 was observed in human cancers, further suggesting an oncogenic role for this factor [16] . Early studies showed that MZF1 might play roles in stemness and in the differentiation of hematopoietic stem cells and indicated its involvement in myeloma [17] .
More recently, MZF1 was shown to participate in the malignant properties of several major solid tumors, including breast [18, 19] , lung [20] , liver [21] , colorectal, and cervical cancer 5 [22] . MZF1 protein structure is composed of an N-terminal SCAN domain, a linker region, and a C-terminal DNA binding domain that contains 13 repeats of zinc finger (ZF) motifs and is a member of the SCAN zinc finger (SCAN-ZF) family [16, 23] . The SCAN domain is leucine-rich oligomerization domain and is highly conserved in the SCAN-ZF family, which is composed of more than 50 family members [24] [25] [26] . Zinc fingerless SCAN domain-only proteins also exist [23] . SCAND1 is a SCAN domain-only protein that has been shown to bind MZF1 and other SCAN-ZF family members. SCAN domain-only proteins have been suspected to be suppressors of intact SCAN-ZF transcriptional activity [23, 24] . This possibility however has remained experimentally untested. Furthermore, we have tested the hypothesis that the relationship between MZF1 and SCAND1 regulates CDC37 expression and thereby cancer growth.
In this report we have, for the first time, characterized the CDC37 gene promoter and determined that MZF1 indeed increases CDC37 expression, while SCAND1 represses CDC37 expression. Our findings provide insight into how MZF1-driven CDC37 expression promotes cancer progression and how SCAND1 functions as a potential tumor suppressor by repressing CDC37.
Results

Elevated expression of CDC37 is caused by MZF1 in prostate cancer.
We first compared the expression levels of CDC37 between prostate cancer cell lines DU-145 and LNCaP, a castration-resistant prostate cancer (CRPC) cell line PC-3, and normal prostate cell line RWPE-1. CDC37 levels in the prostate cancer cells (PC-3, LNCaP, and DU-145) were higher than that of the normal cell line ( Fig 1A) . CDC37 levels in PC-3 cells were higher than that of the other prostate cancer cells in both confluent and growing conditions ( Fig 1A) .
Although there are several possible mechanisms for the elevation in CDC37 expression in prostate cancer, in the present study we have focused on transcriptional regulation as the most immediate level of control. To determine potential cis-acting regulatory elements in the gene, we analyzed the DNA sequence around CDC37 gene, between the -3.6kbp position and +2kbp position counted from the transcription start site (TSS) and found numerous consensus MZF1 binding sequences ( Fig S1) .
To query increased CDC37 level in PC-3 shown in Fig 1A, we next examined MZF1 expression and localization. MZF1 localized in nuclei in PC-3 but in the cytoplasm in PNT2 ( Fig 1B) , suggesting that both expression and nuclear localization of MZF1 could be involved in the increased CDC37 level in PC-3 cells. Additionally, nuclear bodies of MZF1 (designated MZF1-NBs) were seen in PC-3 but not in prostatic normal PNT2 cells, although the significance of the MZF1-NB is currently not known (Fig 1 B, C) . Moreover, MZF1 overexpression led to increases in CDC37 levels in PC-3 cells ( Fig 1D) while siRNA-mediated knockdown of MZF1 lowered CDC37 mRNA and protein levels (Fig 1 E, F) . A role for MZF1 in CDC37 transcription was thus suspected.
To investigate the potential clinical significance of MZF1 regulation of CDC37, we next examined co-expression correlation of MZF1 and CDC37 in prostate cancer patient-derived tumor samples. Co-expression correlation was found between MZF1 and CDC37 in CRPC patient samples (Spearman's rank correlation score: 0.78) and in prostate adenocarcinoma patient samples (Spearman's correlation: 0.41). We next examined MZF1 and CDC37 expression correlation with prognosis of prostate cancer patients. High expression of MZF1 (P=0.0287) and CDC37 (P=0.0182) were correlated with poor prognosis of patients suffering from prostate cancer ( Table 1) .
These data indicated MZF1 to be a potentially causal transcription factor for elevated expression of CDC37 in prostate cancer.
SCAN zinc finger protein MZF1 directly trans-activates the CDC37 gene.
We next queried whether the SCAN zinc finger MZF1 could directly trans-regulate the CDC37 gene through direct binding to cis-elements (MZF1 binding sequences) abundantly found in the CDC37 5'-upstream region. We examined the activities of CDC37 promoter-driven luciferase reporter constructs containing different deletion mutants of the 5' region and examined potential trans-regulation by MZF1 and its SCANless truncation constructs of the factor (Fig 2 A, B ). The full-length native MZF1 markedly increased CDC37 promoter activities (of 3.6k, 950, 500/utr, 500, 202/utr) ( Fig 1C) . The SCANless mutant slightly increased CDC37 promoter activities (of 500/utr, 500, 202/utr) but the transcriptional activity being much reduced compared with SCAN-containing native MZF1. These data indicated that SCAN oligomerization domain is essential for transcriptional activity of MZF1.
It is notable that the 202/utr reporter was more potent in trans-activation compared to other constructs, suggesting the presence of potential inhibitory motifs upstream of the 202 sequence. We next examined whether the overexpressed MZF1 (with Flag-tag) could directly bind to cis-elements in genomic CDC37 promoter region. MZF1 was detected by immunoblot in the crosslinked chromatin fraction and potentially post-translational modification forms (upshift), and potential trimer were detected in the chromatin ( Fig 2D) .
The overexpressed MZF1 occupied genomic CDC37 promoter regions (-0.4k and -1.8k regions that contain MZF1-binding sites) further indicating that the CDC37 gene is regulated by MZF1 binding to these MZF1 binding sites in prostate cancer ( Fig 2E) .
These data indicate that MZF1 directly trans-activates CDC37 gene through direct binding to CDC37 promoter region and the SCAN domain-mediated trimerization is essential for full transcriptional activity of MZF1.
The Zinc-fingerless SCAND1 factor suppresses CDC37 gene and tumorigenesis of prostate cancer
The SCAN-ZF family consists of more than 50 members and contains a few potentially inhibitory zinc fingerless members such as SCAND1. We hypothesized that SCAND1 could repress CDC37 gene transcription through oligomerizing with SCAN-ZF proteins such as MZF1. Notably, SCAND1 is highly expressed in normal prostate compared to the other tissues ( http://biogps.org/#goto=genereport&id=51282 ). We found SCAND1 to be expressed in normal prostate cells while its levels were reduced in prostate cancer PC-3 and DU-145 cells ( Fig 3A) , suggesting that SCAND1 expression declined along with prostate oncogenesis. Overexpression of SCAND1 led to lowered CDC37 levels in PC-3 cells ( Fig. 3B ).
To determine whether SCAND1 and a SCAN-only construct derived from MZF1 could regulate CDC37 promoter constructs, we next carried out co-transfection and reporter assays. SCAND1 and SCAN-only constructs (SCAN and SCAN+linker) derived from truncation of MZF1 significantly repressed CDC37 promoter activities (1.3k/utr, 500/utr, 202/utr) in PC-3 cells ( Fig 3E) . We also confirmed that the native MZF1 protein activated the CDC37 promoter whereas the SCANless mutant had little effect.
We next hypothesized that SCAND1, although lacking ZF domains might be able to associate indirectly with MZF1-binding sites in genomic CDC37 promoter regions, perhaps through SCAND1-SCAN domain of MZF1 interaction. The overexpressed SCAND1 was detected in chromatin in PC-3 as monomer of the expected molecular weight. We also observed potential dimer and higher molecular weight forms in the crosslinked chromatin, suggesting higher oligomerization of SCAND1 on chromatin that might be consistent with a powerful repressor role ( Fig 3F) . The overexpressed SCAND1 (with Flag-tag) occupied the CDC37 promoter region (-1.8k and -0.4k regions that we showed to contain MZF1-binding sites) ( Fig 3G) . The SCAND1 occupancy of the CDC37 regulatory site (-1.8k) was evidently much higher in magnitude than observed with MZF1 and SCAN-only constructs of MZF1 as suggested by increased enrichment in the ChIP assay (comparing Figs 2E, 3G). These data indicated that SCAND1 could repress CDC37 gene powerfully through association with DNA sequences that we showed to bind MZF1. Therefore, our data indicate that while MZF1 positively regulates CDC37, SCAND1 negatively regulates transcription, a finding which could be crucial in mechanisms of prostate cancer progression.
We therefore hypothesized that, in this context, MZF1 has an oncogenic influence while SCAND1 may suppress tumorigenicity. To elucidate this possibility, we asked whether tumor initiation by prostate cancer PC-3 cells could be suppressed by SCAND1 expression and by depletion of MZF1. Indeed, SCAND1 suppressed tumorigenicity of PC-3 cells ( Fig 3H) .
Depletion of MZF1 also lowered tumorigenicity of PC-3 cells.
Discussion
Our data therefore suggest a novel mechanism for prostate cancer regulation by MZF1 ( Fig.   1 ). CDC37 is a crucial molecule in prostate cancer growth through its fostering of oncogenic kinases and our data strongly indicate that the chaperone is regulated by MZF1. We show that MZF1 binds to sites in the CDC37 promoter and strongly activates transcription, and crucially that MZF1 expression is tightly correlated with CDC37 levels in clinical prostate cancer (Figs 1, 2 ). The ability of an endogenous inhibitor, the zinc fingerless SCAND1 factor to bind the promoter and repress transcription of MZF1 suggests a potential mechanism for prostate tumor suppression ( Fig. 3 ). These data suggest mechanisms whereby members of the SCAN transcription factor family can fine-tune prostate cancer growth by up-or down-regulating CDC37 transcription and thus decide the outcome of prostate tumorigenesis (Fig 4) . It is likely that other MZF1 targets important in tumorigenesis may be regulated in a similar way [16] . Our data do not exactly define the mechanism through which SCAND1 represses MZF1 activity although direct co-occupation of the CDC37 promoter appears to be involved ( Fig. 3 ). MZF1 was shown to bind DNA as a homodimer or heterodimer with other SCAN domain proteins and recruit chromatin remodeling protein mDomino [27] . Our data pinpoint the importance of the SCAN domain, as the SCANless construct of MZF1 showed much reduced transcriptional activity compared to the powerful activity of the native MZF1 (Fig. 3E ). The SCAN domain is leucine-rich and mediates oligomer formation [16] . We found that MZF1 could form a higher order structure, potentially a trimer on chromatin ( Fig. 2D ). Therefore, it was indicated that SCAN domain of MZF1 is required for its oligomerization and thus for full activity for trans-activation. Little is currently known regarding the mechanisms whereby SCAND1 could repress transcription, although our data indicate that this may associate with the CDC37 promoter in oligomeric form at the site of MZF1 binding ( Fig. 3 ).
Our studies on CDC37 are aimed ultimately at targeting this factor in cancer as an alternative to Hsp90. Numerous HSP90 inhibitors have been developed to target the abundant HSP90, which plays versatile oncogenic roles in many types of cancer [28] .
However, it has been difficult so far to employ Hsp90 inhibitors at effective doses due to normal tissue toxicity. Depletion of CDC37 reduced prostate cancer cell growth and attenuated MEK-ERK signaling pathway and PI3K-Akt signaling pathway [11] . Moreover, overexpression of CDC37 triggered prostatic tumorigenesis [10] . Our studies therefore suggest that further study of the role of MZF1 and SCAND1 in CDC37 transcription may indicate potential mechanism that may be targeted for inhibition of expression of the chaperone.
In conclusion, it was demonstrated that pro-oncogenic MZF1 and its antagonist SCAND1 coordinately regulate expression of CDC37, a factor that is essential for prostate cancer tumorigenesis. The SCAN domain is required for full transcriptional activity of MZF1
whereas SCAN-only factor SCAND1 powerfully associates with chromatin and represses tumorigenesis of prostate cancer cells.
Materials and Methods
Cell culture. In silico analysis of promoters and gene bodies.
PC
Sequences of promoter regions and gene bodies of human CDC37, HSP90AA1 and HSP90AB1
were obtained from the Eukaryotic Promoter Database [29] . Binding sites for MZF1 were predicted using PROMO [30, 31] .
Luciferase Assay. Transient transfection and luciferase assays were performed as previously described [32] . 
siRNA.
The siRNA were designed based on siRNA design method of JBioS (Japan Bio Services, Saitama). RNA duplex of 19-bp plus TT-3' overhangs in each strand was synthesized by Nippon Gene (Tokyo, Japan). For electroporation-transfection, total 40 pmol siRNA was transfected to 1 to 5 x 10 5 cells. For reagent-transfection, cells were transfected with siRNA at the final concentration of 20-100 nM. Non-targeting siRNA was purchased from Nippon Gene (Tokyo, Japan). The designed sequences of siRNA were listed in Supple Table. Transfection.
For ChIP assay and tumorigenesis assay, electroporation-mediated transfection was performed as described previously [33, 34] . To optimize electroporation for each cell type, cells (1 × 10 5 to 1 × 10 6 cells), plasmid DNA (2 to 10 g total) or siRNA (40 pmol total), and serum-free medium were mixed to 100 l total in a green cuvette with 1-mm gap (NepaGene, Ichikawa, Tokyo) and set to NEPA21 Super Electroporator (NepaGene). Poring pulse was optimized between 100V and 300V for 2.5 or 5.0 msec pulse length twice with 50 msec interval between the pulses and 10% decay rate with + polarity, as shown in a supplemental figure. Transfer pulse condition was five pulses at 20V for 50 msec pulse length with 50 msec interval between the pulses and 40% decay rate with +/-polarity. After electroporation, cells were recovered in serum-contained media. PC-3 (5 × 10 5 cells) was electroporation-transfected with 10 g plasmid DNA or 40 pmol siRNA with poring pulse at 175V for 2.5 msec pulse length twice and then cultured for 5 days and 1 × 10 6 cells were subcutaneously injected to each SCID mouse. DNA was purified from the eluate and from 1% and 10% input chromatin using QIA-Quick DNA purification kit (Qiagen, Hilden, Germany) and eluted within 50 μl of ddH 2 O.
The purified DNA (3-5 μl) was used for ChIP-qPCR. Amplification specificity and efficiency were confirmed with melting curve analysis, slope analysis, and agarose gel electrophoresis.
Primers were listed in Supple Table. Tumorigenesis.
The efforts of all animal experiments were made to minimize suffering. The studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Japanese Pharmacological Society. The protocol was approved by the Animal Care and Use Committee, Okayama University (Permit Number:
OKU-2016219). All animals were held under specific pathogen-free conditions. PC-3 cells (5 × 10 5 ) were transfected with 40 pmol MZF1-targeted siRNA, 10 µg pCMV6-ScanD1-myc-Flag or 10 µg pCMV-EGFP via electroporation, cultured for 5 days, and then 2.5 × 10 6 cells were subcutaneously injected on a back of a 6-7-years-old SCID mouse (CLEA Japan, Tokyo).
Tumor volumes were measured at day 41 post-injection period. The major axis (a) and minor axis (b) of tumors were measured with a caliper. The tumors were deemed to be ellipsoid and the volumes were calculated with a formula as follows: a tumor volume (V) ≒ 4πab 2 /3.
Western blotting.
To compare CDC37 levels among several types of cells, cells were cultured to reach confluent 
Immunocytochemistry.
Immunocytochemistry was performed as described [35] . Cells cultured in 4-well chamber slides were fixed with 4% (wt/vol) paraformaldehyde in PBS for 15 min. Cells were permeabilized with 0.2% Triton X-100 in PBS for 15 min. Cells were blocked in IHC/ICC blocking buffer high protein (eBioscience, San Diego, CA) for 10 min and then reacted with anti-MZF1 antibody (1:50, C10502; Assay Biotechnology, Fremont, CA) and AlexaFluor488 secondary antibody (Thermo Fisher Scientific, 1:1000) in the blocking buffer. Cells were washed with PBS for 5 min twice between the steps. Cells were mounted with ProLong Gold AntiFade Reagent (Thermo Fisher Scientific). Fluorescence images were captured using Axio Vision microscope equipped with an AxioCam MR3 (Zeiss, Oberkochen, Germany).
RT-qPCR.
RT-qPCR was performed as previously described [35, 36] . Total RNA was prepared using an [37] . Primer sequences are listed in Supple Table. Gene expression in clinical samples. Statistics. Data were expressed as the means ± SD unless otherwise specified. Comparisons of 2 were done with an unpaired Student's t-test. 
Co
